Antithrombotic therapy for chronic coronary syndrome and atrial fibrillation: less might be more.

Abstract:

:The best strategy in atrial fibrillation (AF) after > 12 months after an acute coronary syndrome or in patients with chronic coronary syndrome without an indication for interventional revascularization remains unclear. European guidelines generally recommend therapy with oral anticoagulation (OAC) alone, whereas North American guidelines advise combination therapy consisting of OAC plus antiplatelet therapy in some patients. We performed a meta-analysis of available trials comparing these treatment strategies. The primary endpoint was major adverse cardiac events (MACE), secondary endpoints included major bleeding, ischemic and hemorrhagic stroke, myocardial infarction (MI), all-cause mortality, and cardiovascular mortality. Study level data were analyzed. Heterogeneity was assessed using the I2 statistic. risk rates (RR) were calculated using a random-effects model (DerSimonian and Laird). Two randomized trials evaluating 1905 patients were included in this meta-analysis. Rates of MACE (RR 0.91 95% CI 0.58-1.41; p = 0.66; I2 75%), MI (RR 1.75 95% CI 0.87-3.55; p = 0.12; I2 0%) and ischemic stroke (RR 0.83 95% CI 0.53-1.31; p = 0.42; I2 0%) did not differ between the OAC monotherapy and the OAC combination therapy. With regards to safety, rates of major bleeding (RR 0.66 95% CI 0.49-0.91; p = 0.01; I2 0%), and of hemorrhagic stroke (RR 0.43 95% CI 0.19-1.00; p = 0.05; I2 0%) were lower in patients on OAC monotherapy. Based on available evidence summarized in this meta-analysis, we think that primum non nocere still stands true: unless future randomized evidence suggests otherwise, most AF patients should be on OAC monotherapy.

journal_name

J Thromb Thrombolysis

authors

Wernly B,Bhatt DL,Polzin A,Jung C

doi

10.1007/s11239-019-02007-4

subject

Has Abstract

pub_date

2020-02-01 00:00:00

pages

321-324

issue

2

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-019-02007-4

journal_volume

49

pub_type

杂志文章,meta分析
  • D-Dimer elevation and adverse outcomes.

    abstract::D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated D-dimer with adve...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-014-1101-6

    authors: Halaby R,Popma CJ,Cohen A,Chi G,Zacarkim MR,Romero G,Goldhaber SZ,Hull R,Hernandez A,Mentz R,Harrington R,Lip G,Peacock F,Welker J,Martin-Loeches I,Daaboul Y,Korjian S,Gibson CM

    更新日期:2015-01-01 00:00:00

  • Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

    abstract::Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1617-2

    authors: Sartori M,Cosmi B

    更新日期:2018-04-01 00:00:00

  • Hyperthyroidism is associated with shortened APTT and increased fibrinogen values in a general population of unselected outpatients.

    abstract::Although clinical evidence supports a plausible association between thyroid disorders and venous thrombosis, reliable evidence is so far lacking on the potential biological mechanisms and neither temporary nor permanent thromboembolic risk factors were constantly identified. We performed a 2-years retrospective analys...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0269-z

    authors: Lippi G,Franchini M,Targher G,Montagnana M,Salvagno GL,Guidi GC,Favaloro EJ

    更新日期:2009-10-01 00:00:00

  • SARS-CoV-2 infection and thrombotic complications: a narrative review.

    abstract::The current, global situation regarding the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic and its potentially devastating clinical manifestations, i.e. coronavirus disease 2019 (COVID-19), took the world by storm, as millions of people have been infected worldwide and more than 1,600,000 patien...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02374-3

    authors: Moschonas IC,Tselepis AD

    更新日期:2021-01-15 00:00:00

  • Secondary prevention strategies for coronary heart disease.

    abstract::Patients with established coronary heart disease (CHD) have a high risk of subsequent cardiovascular events, including myocardial infarction (MI), stroke, and death from cardiovascular disease. Adherence to evidence-based secondary prevention therapies for CHD has improved in recent years but still remains suboptimal....

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-009-0381-8

    authors: Weiner SD,Rabbani LE

    更新日期:2010-01-01 00:00:00

  • Soluble E-selectin is not a marker of unstable coronary plaque in serum of patients with ischemic heart disease.

    abstract::Increased level of soluble cell adhesion molecules may be a marker for atherosclerosis and/or reflect complication of the atherosclerotic plaque. To test whether expression of cell adhesion molecules is more pronounced in unstable versus stable coronary plaques, we measured the serum level of soluble E-selectin (sE-se...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1018656530541

    authors: Galvani M,Ferrini D,Ottani F,Nanni C,Ramberti A,Amboni P,Iamele L,Vernocchi A,Nicolini FA

    更新日期:2000-01-01 00:00:00

  • A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease.

    abstract::The objective was to compare the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ticagrelor with clopidogrel among subjects of Hispanic ethnicity, as the PD and PK effects of antiplatelet agents among Hispanics are not specifically known. This was a randomised, open-label, crossover PD/PK study of 40 Hispanic...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-014-1135-9

    authors: Price MJ,Clavijo L,Angiolillo DJ,Carlson G,Caplan R,Teng R,Maya J

    更新日期:2015-01-01 00:00:00

  • Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.

    abstract:INTRODUCTION:While the CURE trial demonstrated the benefits of clopidogrel in acute coronary syndromes, patients receiving glycoprotein IIb/IIIa antagonists were excluded. Given the frequent coadministration of these two medications, we sought to examine their interaction and their combined effect on platelet inhibitio...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-004-0170-3

    authors: Talreja D,Lubbe D,Orford JL,Lennon R,DiBattiste PM,Berger PB

    更新日期:2004-08-01 00:00:00

  • COVID-19 associated coagulopathy in critically ill patients: A hypercoagulable state demonstrated by parameters of haemostasis and clot waveform analysis.

    abstract::Patients with COVID-19 are known to be at risk of developing both venous, arterial and microvascular thrombosis, due to an excessive immuno-thrombogenic response to the SARS-CoV-2 infection. Overlapping syndromes of COVID-19 associated coagulopathy with consumptive coagulopathy and microangiopathy can be seen in criti...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02318-x

    authors: Fan BE,Ng J,Chan SSW,Christopher D,Tso ACY,Ling LM,Young BE,Wong LJL,Sum CLL,Tan HT,Ang MK,Lim GH,Ong KH,Kuperan P,Chia YW

    更新日期:2020-10-24 00:00:00

  • Prevalence of Factor V 1691 G-A (Leiden) and prothrombin G20210A polymorphisms and the risk of venous thrombosis among cancer patients.

    abstract:AIMS:Cancer patients have an increased risk for thromboembolism (TE). Factor V 1691 G-A(Leiden) (FVL) and prothrombin (PT) G20210A mutation are common inherited risk factor for TE. The aim of the study is to evaluate the prevalence of FVL and PT G20210A polymorphism in cancer patients with and without TE as compared to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-006-9001-z

    authors: Eroglu A,Ulu A,Cam R,Kurtman C,Akar N

    更新日期:2007-02-01 00:00:00

  • Relationship between biomarkers and subsequent clinical and angiographic restenosis after paclitaxel-eluting stents for treatment of STEMI: a HORIZONS-AMI substudy.

    abstract::Drug-eluting stents (DES) reduce the incidence of in-stent restenosis (ISR) after primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI). Whether the use of biomarkers might be of utility to identify patients who remain at risk for DES ISR after primary PCI has never been exami...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-012-0706-x

    authors: Claessen BE,Stone GW,Mehran R,Witzenbichler B,Brodie BR,Wöhrle J,Witkowski A,Guagliumi G,Zmudka K,Henriques JP,Tijssen JG,Sanidas EA,Chantziara V,Hakim D,Leon S,Xu K,Dangas GD

    更新日期:2012-08-01 00:00:00

  • Antithrombin after cardiac surgery: implications on short and mid-term outcome.

    abstract:BACKGROUND:Antithrombin (AT) drop during cardiac surgery has been described. The causes and the effects of this phenomenon are not clear. The objective of the study is to evaluate the relationship of AT postoperative values on short and mid-term outcome after cardiac surgery. METHODS:Between January and June 2005, 405...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0191-9

    authors: Paparella D,Cappabianca G,Scrascia G,Fiore G,Paramythiotis A,Di Bari N,Liuzzi MP,Ibrahim MF,Fiore T,de Luca Tupputi Schinosa L

    更新日期:2009-01-01 00:00:00

  • Monitoring the roles of prothrombin activation fragment 1 and 2 (F1 + 2) in patients with atrial fibrillation receiving rivaroxaban and apixaban.

    abstract::Factor Xa (FXa) inhibitors are recommended for use in fixed doses without laboratory monitoring. However, prior studies reported the importance of establishing biomarkers representing anticoagulation intensity related to bleeding or thrombotic events. To test the hypothesis that prothrombin activation fragment 1 and 2...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02079-7

    authors: Ueno EI,Fujibayashi K,Sawaguchi J,Yasuda Y,Takano S,Fujioka N,Kawai Y,Fujita H,Tanaka Y,Kajinami K

    更新日期:2020-08-01 00:00:00

  • Unfavourably altered plasma clot properties in patients with primary Raynaud's phenomenon: association with venous thromboembolism.

    abstract::Associations of Raynaud's phenomenon (RP) with venous thromboembolism (VTE) are unclear. We investigated the occurrence of RP together with prothrombotic state markers and fibrin clot properties in VTE patients. In this prospective cohort study we enrolled 360 patients free of known autoimmune disease. D-dimer, von Wi...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01805-0

    authors: Żuk J,Snarska-Drygalska A,Malinowski KP,Papuga-Szela E,Natorska J,Undas A

    更新日期:2019-02-01 00:00:00

  • Thromboembolic events in patients with severe inherited fibrinogen deficiency.

    abstract::Inherited afibrinogenemia and hypofibrinogenemia are rare bleeding disorders characterized by markedly reduced levels of fibrinogen in blood. Thrombotic complications in these disorders have been rarely described. We performed a multicenter retrospective study and reviewed the occurrence of thrombotic complications am...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-015-1325-0

    authors: Rottenstreich A,Lask A,Schliamser L,Zivelin A,Seligsohn U,Kalish Y

    更新日期:2016-08-01 00:00:00

  • Evaluation of a rapid turn-over, fully-automated ADAMTS13 activity assay: a method comparison study.

    abstract::Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severely reduced activity of the von-Willebrand factor-cleaving protease ADAMTS13, mainly caused by anti-ADAMTS-13 antibodies. Although several test systems for ADAMTS13 measurement exist, long turn-around times hamper...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02086-8

    authors: Stratmann J,Ward JN,Miesbach W

    更新日期:2020-10-01 00:00:00

  • Renal Vein Thrombosis and Selective Arterial or Venous Thrombolytic Therapy.

    abstract::Background: Renal vein thrombosis (RVT) complicating the nephrotic syndrome is associated with a poor prognosis. Methods/Results: RVT was diagnosed in 12 of 60 patients with a diagnosis of nephrotic syndrome suggested by computed tomography (CT) and subsequently confirmed by selective renal angiography. Fifty patients...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF00226414

    authors: Wu ZL,Zhou KR,Liao Lt

    更新日期:1996-01-01 00:00:00

  • Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity.

    abstract::Hyperhomocysteinemia (HHcy) affects haemostasis and shifts its balance in favour of thrombosis. In vitro and in vivo studies suggested that HHcy may impair fibrinolysis either by influencing the plasma levels of fibrinolytic factors or by altering the fibrinogen structure. We investigated the influence of mild HHcy le...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0981-1

    authors: Cellai AP,Lami D,Antonucci E,Liotta AA,Rogolino A,Fedi S,Fiorillo C,Becatti M,Cenci C,Marcucci R,Abbate R,Prisco D

    更新日期:2014-07-01 00:00:00

  • Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy.

    abstract::Infarct artery stenting with adjunctive abciximab therapy is widely used treatment for patients with acute myocardial infarction (AMI). However, bleeding complications have been associated with a worse clinical outcome. Randomized trials in elective patients have shown that postprocedural protamine administration is s...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-010-0481-5

    authors: Parodi G,De Luca G,Moschi G,Bellandi B,Valenti R,Migliorini A,Carrabba N,Antoniucci D

    更新日期:2010-11-01 00:00:00

  • Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

    abstract::Warfarin is the most widely prescribed oral anticoagulant, but large interindividual variations exist in the dose required to achieve comparable therapeutic effects. Several clinical and genetic variables have been identified that influence warfarin dosing. However, interactions between genotype and nutrition remain u...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0978-9

    authors: Saito R,Takeda K,Yamamoto K,Nakagawa A,Aoki H,Fujibayashi K,Wakasa M,Motoyama A,Iwadare M,Ishida R,Fujioka N,Tsuchiya T,Akao H,Kawai Y,Kitayama M,Kajinami K

    更新日期:2014-07-01 00:00:00

  • Platelet glycoprotein Ibalpha gene polymorphism and massive or submassive pulmonary embolism.

    abstract:OBJECTIVE:The -5T/C polymorphism in the Kozak sequence of glycoprotein Ibalpha, a component of the platelet glycoprotein Ib-IX-V receptor complex, is associated with an increase in this receptor density on the surface of the platelet. This study was designed to investigate the effect of platelet glycoprotein Ibalpha Ko...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-008-0204-3

    authors: Soylu A,Tokaç M,Cora T,Düzenli MA,Acar H

    更新日期:2009-04-01 00:00:00

  • The recognition of acute coronary ischemia in the outpatient setting.

    abstract:BACKGROUND:The missed diagnosis of acute myocardial infarction has been studied in the Emergency Department, but few studies have investigated how often coronary ischemia is correctly identified in the outpatient setting. METHODS:This was a single center retrospective observational study of patients with Health Allian...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0153-2

    authors: Jaffery Z,Hudson MP,Khanal S,Ananthasubramaniam K,Kim H,Greenbaum A,Kugelmass A,Jacobsen G,McCord J

    更新日期:2009-01-01 00:00:00

  • Calcific embolization with infective endocarditis involving the posterior mitral leaflet in a patient with underlying hypertrophic obstructive cardiomyopathy.

    abstract::We report a case of infective endocarditis (IE) involving the posterior mitral leaflet (PML) with calcific embolization in a patient with hypertrophic obstructive cardiomyopathy (HOCM). Amongst HOCM patients with IE, the anterior mitral leaflet and basal septal myocardium are almost always involved due to the endocard...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1111-4

    authors: Lather N,Niziolek K,Toth P,Harris DM

    更新日期:2015-02-01 00:00:00

  • Impact of type of thrombolytic agent on in-hospital outcomes in ST-segment elevation myocardial infarction patients in the Middle East.

    abstract::Little is known about the impact of thrombolytic agents on in-hospital outcomes in the Middle East. The objective of this study was to evaluate the impact of thrombolytic agents on in-hospital outcomes in ST-segment elevation myocardial infarction (STEMI) patients in six Middle Eastern countries. Gulf Registry of Acut...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究

    doi:10.1007/s11239-012-0698-6

    authors: Al-Zakwani I,Ali A,Zubaid M,Panduranga P,Sulaiman K,Abusham A,Almahmeed W,Al-Motarreb A,Al Suwaidi J,Amin H

    更新日期:2012-04-01 00:00:00

  • Acute Myocardial Infarction in Canada: New Epidemiologic Insights on Incidence, Therapy, and Risk.

    abstract::Objective: To define the changing incidence, risk, and therapy of acute myocardial infarction (A311). Data sources: Review of contemporary AMI data from the University of Alberta Hospitals, six other sites of the Clinical Quality Improvement Network (CQIN), and other Canadian and international centers. Data synthesis:...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF00132402

    authors: Montague T,Montague P,Barnes M,Taylor L,Wowk L,Fassbender K,Ackman M,Martin S,Armstrong PW,Teo K

    更新日期:1996-01-01 00:00:00

  • Asymmetric dimethylarginine and impaired cardiovascular healing.

    abstract::Asymmetric dimethylarginine (ADMA) typically accumulates in the plasma of patients with chronic renal failure. Moreover, its plasma levels are raised in the presence of virtually all of the traditional cardiovascular risk factors. ADMA inhibits the three isoforms of nitric oxide (NO) synthase, thereby blunting the kno...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0181-y

    authors: Coluzzi G,Santucci E,Marzo F,Andreotti F

    更新日期:2009-02-01 00:00:00

  • Factors influencing early neurological improvement after mechanical thrombectomy among patients with acute basilar artery occlusion: a single center prospective observational cohort study.

    abstract::The predictive value of and the influencing factors associated with early neurological improvement (ENI) among patients with acute basilar artery occlusion (BAO) have not been well studied. The present study aimed to evaluate whether ENI predicted a better functional outcome and to identify the influencing factors of ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02153-0

    authors: Sun X,Zhang H,Tong X,Gao F,Deng Y,Ma G,Ma N,Mo D,Song L,Liu L,Huo X,Miao Z

    更新日期:2021-01-01 00:00:00

  • Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.

    abstract:BACKGROUND:Venous thromboembolism (VTE) is a significant cause of mortality and morbidity in medical patients. Although thromboprophylaxis with enoxaparin reduces the risk of VTE in these patients, the optimal duration of therapy is not currently known. The EXCLAIM (EXtended CLinical prophylaxis in Acutely Ill Medical ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,随机对照试验

    doi:10.1007/s11239-006-7732-5

    authors: Hull RD,Schellong SM,Tapson VF,Monreal M,Samama MM,Turpie AG,Wildgoose P,Yusen RD

    更新日期:2006-08-01 00:00:00

  • Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles.

    abstract::Monocytes and monocyte-derived microparticles (MMPs) play a major role in acute coronary syndrome (ASC). Activated monocytes (ac-M) and MMPs support thrombin generation via tissue factor (TF). The aim of this study was to evaluate the inhibitory effect of fondaparinux, a selective Xa inhibitor, on thrombin generation ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-010-0490-4

    authors: Ben-Hadj-Khalifa-Kechiche S,Hezard N,Poitevin S,Remy MG,Florent B,Mahjoub T,Nguyen P

    更新日期:2010-11-01 00:00:00

  • The impact of proton therapy on cardiotoxicity following radiation treatment.

    abstract::Cardiac disease following radiation therapy represents a major consideration in the treatment of a variety of malignancies. Damage to the heart can manifest in a variety of pathologies including ischemic cardiac disease, cardiomyopathy, valvular dysfunction, arrhythmias, and pericarditis. This damage has been shown to...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-020-02303-4

    authors: Frankart AJ,Nagarajan R,Pater L

    更新日期:2020-10-08 00:00:00